<DOC>
	<DOCNO>NCT01957904</DOCNO>
	<brief_summary>The study design confirm acute safety performance ArterXÂ® Surgical Sealant hemostatic agent . The study collect data support publication future product label revision , provide additional clinical information use detail regard product safety .</brief_summary>
	<brief_title>ArterX Safety Efficacy Study Cardiac Indications</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>&gt; 18 year age , Male female If female , subject postmenopausal , child bear potential negative serum urine pregnancy test within 7 day index procedure practice abstinence highly effective method contraception duration study . The subject guardian must provide write Informed Consent use form review approved Ethics Committee . The subject willing able contact 3 month followup attend followup visit need per protocol . The subject determine surgeon risk poor hemostasis . Subject undergoing emergency surgery . Subject undergo minimally invasive surgery . Subject clinically significant medical , psychiatric , cognitive illness drug/alcohol abuse opinion investigator would affect subject 's safety compliance study assessment followup . Subject immune system disorders/immunodeficiency immunosuppression . Subject participate another clinical study within 30 day prior surgery received investigational drug device within past 30 day . Subject pregnant , may become pregnant currently breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ArterX , surgical sealant</keyword>
</DOC>